WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19

WHO ’s prequalification adds to several mechanisms already in place to improve access to Actemra/RoActemra for people with COVID-19 in low- and middle-income countriesSince the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra, as recommended in global treatment guidelinesTwelfth Roche medicine or test to be prequalified Basel, 11 February 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Actemra ®/RoActemra® (tocilizumab) intravenous (IV) has been granted World Health Organization (WHO) prequalification. Prequalification is a confirmation by WHO that Actemra/RoActemra meets the WHO standards for quality, safety and efficacy for the treatment of COVID-19 in adults who are receiving systemi c corticosteroids and require supplemental oxygen or mechanical ventilation.1 It helps procurers in low- and middle-income countries identify priority medicines to improve access to care and support better health.“People from many low- and middle-income countries continue to feel the devastating impact of COVID-19, and care needs remain unprecedented,” said Bill Anderson, Chief Executive Officer of Roche Pharmaceuticals. “We’ve partnered with WHO and others throughout the last year to ensure that our COVID-19 medicines and tests can potentially reach more than 100 low- and middle-income countries, and WHO’s prequalification of Actemra/RoActemra is just one of the paths taken together to ach...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news